DDInter1620 DDInter1626
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185]
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) resembles {v} (Compound) Levobupivacaine
Levobupivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rucaparib
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Rilonacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) resembles {v} (Compound) Tocainide
Tocainide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) binds {v} (Gene) SCN10A
SCN10A {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) resembles {v} (Compound) Tocainide
Tocainide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Ropivacaine {u} (Compound) binds {v} (Gene) SCN10A
SCN10A {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Rucaparib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) resembles Levobupivacaine (Compound) and Levobupivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) resembles Tocainide (Compound) and Tocainide may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) binds SCN10A (Gene) and SCN10A (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) resembles Tocainide (Compound) and Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ropivacaine (Compound) binds SCN10A (Gene) and SCN10A (Gene) is bound by Procainamide (Compound) and Procainamide may lead to a major life threatening interaction when taken with Rucaparib